Sensitizing chemicals may induce sensitization of the respiratory tract, leading to symptoms known as occupational asthma.
That is how many biomarkers our test consists of.
GARDair™ is an in vitro assay in development for predicition of chemical respiratory sensitizers.
There are currently no available method for accurate prediction and classification of chemical respiratory sensitizers. The development of GARDair™ is the first of its kind, and the research is supported by EU Horizon 2020.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 756014.
Tests for respiratory allergy are rare!
“By combining SenzaGen’s technological expertise and our experience with inhaled compounds, we aim to develop a novel method to investigate whether novel drug-like molecules induce similar genomic signatures as known respiratory irritants.”
AstraZeneca Gothenburg, Collaborative partner in GARDair™ development project
SenzaGen AB, Medicon Village
223 81 Lund, Sweden